Curated News
By: NewsRamp Editorial Staff
September 03, 2025
GeoVax to Present Key Vaccine and Cancer Therapy Updates at Investment Conference
TLDR
- GeoVax's pipeline advancements position investors for potential gains from vaccines targeting COVID-19, Mpox, and cancer therapies with upcoming Phase 2 and 3 trials.
- GeoVax uses its MVA platform and continuous cell line manufacturing to develop multi-antigen vaccines undergoing Phase 2 trials for COVID-19 and oncology applications.
- GeoVax's vaccines for immunocompromised patients and cancer therapies aim to improve global health security and treatment outcomes for vulnerable populations.
- GeoVax is advancing a novel gene-directed enzyme prodrug therapy for head and neck cancer alongside next-generation vaccines for infectious diseases.
Impact - Why it Matters
This news matters because GeoVax's vaccine and immunotherapy programs address critical public health needs, including pandemic preparedness, protection for immunocompromised populations, and advanced cancer treatments. Their progress in developing next-generation vaccines for Mpox/smallpox and COVID-19 could significantly enhance global biosecurity and provide more effective protection for vulnerable patient groups. The company's focus on solid tumor therapies like Gedeptin® represents important advancements in oncology treatment, potentially offering new options for patients with difficult-to-treat cancers. For investors and the healthcare community, these developments signal important progress in biotechnology that could lead to improved public health outcomes and new medical solutions.
Summary
GeoVax Labs, Inc., a clinical-stage biotechnology company, announced that Chairman and CEO David Dodd will present key updates on the company's vaccine and immunotherapy programs at the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025. The presentation, available via webcast, will cover recent progress and upcoming milestones for three major programs: GEO-MVA, a next-generation Mpox/smallpox vaccine that recently received favorable Scientific Advice from the European Medicines Agency; GEO-CM04S1, a multi-antigen COVID-19 vaccine currently in three Phase 2 clinical trials for various patient populations including immunocompromised individuals; and Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors with an upcoming Phase 2 trial in head and neck cancer.
The company will also emphasize how its MVA platform and U.S.-based continuous cell line manufacturing capabilities position GeoVax to address critical gaps in vaccine supply diversification, pandemic readiness, and biosecurity. Institutional investors interested in attending the conference and scheduling meetings with GeoVax leadership are encouraged to contact their H.C. Wainwright representative. For more information about the company's clinical trials and updates, visit their website at www.geovax.com, which serves as a comprehensive resource for investors and stakeholders following the company's progress in developing innovative solutions for infectious diseases and cancer treatment.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, GeoVax to Present Key Vaccine and Cancer Therapy Updates at Investment Conference
